Literature DB >> 7586374

Cardiac renin-angiotensin system in the hypertrophied heart.

N Iwai1, H Shimoike, M Kinoshita.   

Abstract

BACKGROUND: The cardiac renin-angiotensin system (RAS) has been suggested to play an important role in heart failure and cardiac hypertrophy. In the present study, we evaluated the expression of each component of the RAS in hypertrophied heart induced by aortocaval shunt. METHODS AND
RESULTS: The expression levels of renin, angiotensinogen, angiotensin-converting enzyme (ACE), and angiotensin II type Ia and Ib receptor (AT1aR and AT1bR) mRNA were determined by the reverse transcription-polymerase chain reaction method owing to the relatively low expression levels of these mRNAs in the ventricle. The expression level of renin or angiotensinogen mRNA in the ventricle was very low, more than 1000-fold lower than that in the kidney or liver, respectively. The expression of ACE mRNA in the ventricle was relatively abundant and was increased in the hypertrophied ventricle in this model, whereas no significant increases in the expression levels of AT1aR and AT1bR mRNA were observed. Administration of lisinopril attenuated the development of left and right ventricular hypertrophy in this model and was accompanied by an attenuation of the upregulation of the ACE, collagen type I-alpha, and vimentin mRNAs. Because the activity of the circulating RAS in the aortocaval shunt rats was not higher than that in the sham-operated rats, the effects of lisinopril in attenuating the ventricular hypertrophy may be due to inhibition of the increased ACE in the ventricle.
CONCLUSIONS: The present study supports the importance of ACE expressed in the ventricle in the development of hypertrophy induced by aortocaval shunt.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586374     DOI: 10.1161/01.cir.92.9.2690

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

Review 1.  Fetal cardiovascular physiology.

Authors:  J Rychik
Journal:  Pediatr Cardiol       Date:  2004 May-Jun       Impact factor: 1.655

2.  Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block.

Authors:  L Hein; M E Stevens; G S Barsh; R E Pratt; B K Kobilka; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces.

Authors:  L J Dell'Italia; Q C Meng; E Balcells; C C Wei; R Palmer; G R Hageman; J Durand; G H Hankes; S Oparil
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

4.  Involvement of gp130-mediated signaling in pressure overload-induced activation of the JAK/STAT pathway in rodent heart.

Authors:  J Pan; K Fukuda; H Kodama; M Sano; T Takahashi; S Makino; T Kato; T Manabe; S Hori; S Ogawa
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

Review 5.  The renin-angiotensin system and the heart: beyond 2000.

Authors:  T Morgan; H R Brunner
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

6.  Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis.

Authors:  A Leri; Y Liu; P P Claudio; J Kajstura; X Wang; S Wang; P Kang; A Malhotra; P Anversa
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

7.  Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene.

Authors:  Xiaobin Han; Jed Ross; Ganesh Kolumam; Min Pi; Junichiro Sonoda; Gwendalyn King; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2017-10-09       Impact factor: 10.121

Review 8.  Uncoupling the Vicious Cycle of Mechanical Stress and Inflammation in Calcific Aortic Valve Disease.

Authors:  Nalin H Dayawansa; Sara Baratchi; Karlheinz Peter
Journal:  Front Cardiovasc Med       Date:  2022-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.